Document Detail

Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent.
MedLine Citation:
PMID:  8552516     Owner:  NLM     Status:  MEDLINE    
To investigate the clinical effects of MS-551, a Class III antiarrhythmic agent, 11 patients underwent electrophysiological study. MS-551 was given intravenously as an initial dose of 0.2 or 0.3 mg/kg for 5 minutes followed by the continuous infusion at 0.2 or 0.3 mg/kg for 30 minutes, respectively, in all patients. The rate corrected QT interval increased significantly from 3 minutes after the beginning of MS-551 infusion. The sinus heart rate decreased significantly by 8% at 10 minutes after the drug administration (P < 0.025). Mean PR and QRS intervals, and blood pressure were not significantly affected by the drug. Mean PA, AH, and HV intervals during sinus rhythm were also not affected. The effective refractory periods (ERPs) of the atrium and ventricle were significantly prolonged by 13% from 202 +/- 24 ms to 231 +/- 26 ms (P < 0.0005), and by 7% from 238 +/- 11 ms to 257 +/- 13 ms (P < 0.002), respectively, by MS-551. The ERP of the atrioventricular node and sinoatrial nodal recovery time were not changed significantly by the drug. This is a report of the effects of MS-551 in humans. This agent could be useful for treatment of tachyarrhythmias by prolongation of ERPs of the atrium and ventricle without significant variations of blood pressure and intracardiac conduction times. It is noteworthy that MS-551 slightly but significantly decreased heart rate.
S Isomoto; A Konoe; O A Centurion; M Hayano; M Kaibara; T Hirata; K Yano
Related Documents :
8422266 - Combined use of labetalol and nifedipine in controlling the cardiovascular response fro...
1012336 - On the action of nifedipine under conditions of variable stimulation patterns and [ca2+...
9243256 - Effect of efonidipine, a novel dihydropyridine derivative, on myocardial metabolic chan...
8027926 - Comparative study of buccoadhesive formulations and sublingual capsules of nifedipine.
1357246 - Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn.
11693776 - Alpha-methylnorepinephrine, a selective alpha2-adrenergic agonist for cardiac resuscita...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pacing and clinical electrophysiology : PACE     Volume:  18     ISSN:  0147-8389     ISO Abbreviation:  Pacing Clin Electrophysiol     Publication Date:  1995 Nov 
Date Detail:
Created Date:  1996-02-21     Completed Date:  1996-02-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7803944     Medline TA:  Pacing Clin Electrophysiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2022-7     Citation Subset:  IM    
Third Department of Internal Medicine, Nagasaki University School of Medicine, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / administration & dosage,  blood,  therapeutic use*
Atrial Fibrillation / drug therapy*,  physiopathology
Atrioventricular Node / drug effects
Blood Pressure / drug effects
Bundle of His / drug effects
Electrocardiography / drug effects
Heart Atria / drug effects
Heart Rate / drug effects
Heart Ventricles / drug effects
Infusions, Intravenous
Injections, Intravenous
Middle Aged
Pyrimidinones / administration & dosage,  blood,  therapeutic use*
Refractory Period, Electrophysiological / drug effects
Sinoatrial Node / drug effects
Tachycardia / drug therapy
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Pyrimidinones; 130656-51-8/MS 551

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Estimation of temperature during radiofrequency catheter ablation using impedance measurements.
Next Document:  Adverse pacemaker hemodynamics evaluated by pulmonary venous flow monitoring.